Vistagen Therapeutics (VTGN) Assets (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Assets of $48.6 million for Q1 2026, down 25.35% sequentially from $65.1 million in Q4 2025, and down 42.42% YoY from $84.3 million in Q1 2025.
Vistagen Therapeutics (VTGN) Assets (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Assets for 14 years, with the latest figure at $48.6 million in Q1 2026.
- Quarterly Assets fell 42.42% year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.6 million (down 42.42% YoY) and the FY2026 annual result came in at $48.6 million, down 42.42% from the prior year.
- Assets fell to $48.6 million in Q1 2026 per VTGN's latest filing, from $65.1 million in the prior quarter.
- Over five years, Assets peaked at $131.1 million in Q4 2023 and troughed at $15.0 million in Q2 2023.
- A 5-year average of $70.2 million and a median of $68.9 million in 2025 frame the typical range for Assets.
- The sharpest annual moves came in 2023 and 2024: Assets tumbled 74.4% in 2023, then jumped 655.36% in 2024.
- Over 5 years, Assets stood at $29.7 million in 2022, then jumped by 341.18% to $131.1 million in 2023, then declined by 29.57% to $92.3 million in 2024, then dropped by 29.52% to $65.1 million in 2025, then fell by 25.35% to $48.6 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $48.6 million, $65.1 million, and $80.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Vistagen Therapeutics | 10.53 Mn | 10.53 Mn | - | 35.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.56 Mn |
| Dec 31, 2025 | 65.06 Mn |
| Sep 30, 2025 | 80.93 Mn |
| Jun 30, 2025 | 68.92 Mn |
| Mar 31, 2025 | 84.34 Mn |
| Dec 31, 2024 | 92.31 Mn |
| Sep 30, 2024 | 102.50 Mn |
| Jun 30, 2024 | 113.55 Mn |
| Mar 31, 2024 | 123.65 Mn |
| Dec 31, 2023 | 131.07 Mn |
| Sep 30, 2023 | 42.20 Mn |
| Jun 30, 2023 | 15.03 Mn |
| Mar 31, 2023 | 21.09 Mn |
| Dec 31, 2022 | 29.71 Mn |
| Sep 30, 2022 | 40.70 Mn |
| Jun 30, 2022 | 58.73 Mn |
| Mar 31, 2022 | 74.64 Mn |
| Dec 31, 2021 | 90.54 Mn |
| Sep 30, 2021 | 100.50 Mn |
| Jun 30, 2021 | 103.91 Mn |